499 related articles for article (PubMed ID: 19028575)
1. Kinetic modelling of NSAID action on COX-1: focus on in vitro/in vivo aspects and drug combinations.
Goltsov A; Maryashkin A; Swat M; Kosinsky Y; Humphery-Smith I; Demin O; Goryanin I; Lebedeva G
Eur J Pharm Sci; 2009 Jan; 36(1):122-36. PubMed ID: 19028575
[TBL] [Abstract][Full Text] [Related]
2. Kinetic basis for selective inhibition of cyclo-oxygenases.
Gierse JK; Koboldt CM; Walker MC; Seibert K; Isakson PC
Biochem J; 1999 May; 339 ( Pt 3)(Pt 3):607-14. PubMed ID: 10215599
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics and pharmacokinetics of nonsteroidal anti-inflammatory drugs in species of veterinary interest.
Lees P; Landoni MF; Giraudel J; Toutain PL
J Vet Pharmacol Ther; 2004 Dec; 27(6):479-90. PubMed ID: 15601442
[TBL] [Abstract][Full Text] [Related]
4. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
Rahme E; Bardou M; Dasgupta K; Toubouti Y; Ghosn J; Barkun AN
Rheumatology (Oxford); 2007 Feb; 46(2):265-72. PubMed ID: 16844699
[TBL] [Abstract][Full Text] [Related]
5. PK-PD integration and PK-PD modelling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology.
Lees P; Giraudel J; Landoni MF; Toutain PL
J Vet Pharmacol Ther; 2004 Dec; 27(6):491-502. PubMed ID: 15601443
[TBL] [Abstract][Full Text] [Related]
6. Genetic tools to tailor cancer prevention by NSAIDs.
Ulrich CM; Bigler J; Potter JD
Discov Med; 2006 Apr; 6(32):71-4. PubMed ID: 17234129
[TBL] [Abstract][Full Text] [Related]
7. Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
Umar A; Boisseau M; Yusup A; Upur H; Bégaud B; Moore N
Fundam Clin Pharmacol; 2004 Oct; 18(5):559-63. PubMed ID: 15482377
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of 2 celecoxib derivatives: analgesic effect and selectivity to cyclooxygenase-2/1.
Lu ZH; Xiong XY; Zhang BL; Lin GC; Shi YX; Liu ZG; Meng JR; Zhou YM; Mei QB
Acta Pharmacol Sin; 2005 Dec; 26(12):1505-11. PubMed ID: 16297351
[TBL] [Abstract][Full Text] [Related]
9. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
King JN; Dawson J; Esser RE; Fujimoto R; Kimble EF; Maniara W; Marshall PJ; O'Byrne L; Quadros E; Toutain PL; Lees P
J Vet Pharmacol Ther; 2009 Feb; 32(1):1-17. PubMed ID: 19161451
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis.
Tanaka K; Suemasu S; Ishihara T; Tasaka Y; Arai Y; Mizushima T
Eur J Pharmacol; 2009 Jan; 603(1-3):120-32. PubMed ID: 19101538
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the nonsteroidal anti-inflammatory drug literature for potential developmental toxicity in rats and rabbits.
Cook JC; Jacobson CF; Gao F; Tassinari MS; Hurtt ME; DeSesso JM
Birth Defects Res B Dev Reprod Toxicol; 2003 Feb; 68(1):5-26. PubMed ID: 12852480
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and anti-inflammatory evaluation of a series of novel amino acid-binding 1,5-diarylpyrazole derivatives.
Li MH; Yin LL; Cai MJ; Zhang WY; Huang Y; Wang X; Zhu XZ; Shen JK
Acta Pharmacol Sin; 2005 Jul; 26(7):865-72. PubMed ID: 15960895
[TBL] [Abstract][Full Text] [Related]
14. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?
Hersh EV; Lally ET; Moore PA
Curr Med Res Opin; 2005 Aug; 21(8):1217-26. PubMed ID: 16083531
[TBL] [Abstract][Full Text] [Related]
15. Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells.
Lev-Ari S; Strier L; Kazanov D; Elkayam O; Lichtenberg D; Caspi D; Arber N
Rheumatology (Oxford); 2006 Feb; 45(2):171-7. PubMed ID: 16249246
[TBL] [Abstract][Full Text] [Related]
16. Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.
Liccardi G; Salzillo A; Piccolo A; Senna G; Piscitelli E; D'Amato M; D'Amato G
Eur Ann Allergy Clin Immunol; 2005 Feb; 37(2):50-3. PubMed ID: 15859361
[TBL] [Abstract][Full Text] [Related]
17. Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?
Chen JT; Pucino F; Resman-Targoff BH
J Pain Palliat Care Pharmacother; 2006; 20(4):11-32. PubMed ID: 17182503
[TBL] [Abstract][Full Text] [Related]
18. Differential inhibition of cyclooxygenase isoenzymes in the cat by the NSAID robenacoxib.
Giraudel JM; Toutain PL; King JN; Lees P
J Vet Pharmacol Ther; 2009 Feb; 32(1):31-40. PubMed ID: 19161453
[TBL] [Abstract][Full Text] [Related]
19. Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers.
Elnachef N; Scheiman JM; Fendrick AM; Howden CW; Chey WD
Aliment Pharmacol Ther; 2008 Nov; 28(10):1249-58. PubMed ID: 18729848
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting.
Davis TW; Zweifel BS; O'Neal JM; Heuvelman DM; Abegg AL; Hendrich TO; Masferrer JL
J Pharmacol Exp Ther; 2004 Mar; 308(3):929-34. PubMed ID: 14711936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
